Dose Ranging Study in Healthy Methadone Maintenance Subjects
Information source: Wyeth
Information obtained from ClinicalTrials.gov on December 31, 2007
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Adult
Intervention: MOA-728 (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Wyeth Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Wyeth Research
Summary
To assess the effect of a single oral dose of MOA-728, an investigational drug, on the
oral-cecal transit time in subjects who are taking methadone.
Clinical Details
Official title: A Randomized, Double-Blind, 4-Period Crossover, Dose-Ranging Study to Determine the Effects on the Oral-Cecal Transit Time of Single Doses of MOA-728 and the Safety and Tolerability of Multiple Doses of MOA-728 in Stable Methadone Maintenance Subjects
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Pharmacokinetics/Dynamics Study
Primary outcome: Oral-cecal transit time will be evaluated.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Men or nonlactating and nonpregnant women, aged 18 to 65 years
Healthy as determined by the investigator on the basis of medical history, physical
examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram
Locations and Contacts
Lenexa, Kansas 66219, United States
Additional Information
Starting date: June 2006
Ending date: September 2006
Last updated: March 30, 2007
|
